Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed classical Hodgkin's lymphoma~  * No lymphocyte-predominant histology~ * Stage II, III, or IV disease~ * Newly diagnosed disease~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Creatinine \< 2.0 mg/dL~* Bilirubin \< 5 mg/dL~* Not pregnant or nursing~* No HIV positivity~* Hepatitis B surface antigen negative~* No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for Hodgkin's lymphoma~* Steroids allowed if medically required before chemotherapy initiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- R-ABVD (Type: EXPERIMENTAL): ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m\^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m\^2 Cycles 2, 4, and 6 Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).